Cargando…
A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants
Population pharmacokinetic (PPK) modelling is an easy and impartment method for estimating drug concentration for use inindividualized therapy, especially for young patients and to help protect drug-induced diseases. The purpose of this study was to develop a PPK model for effective dosing of vancom...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739632/ https://www.ncbi.nlm.nih.gov/pubmed/29285245 http://dx.doi.org/10.18632/oncotarget.22114 |
_version_ | 1783287902750375936 |
---|---|
author | Song, Lin He, Cui-Yao Yin, Nan-Ge Liu, Fang Jia, Yun-Tao Liu, Yao |
author_facet | Song, Lin He, Cui-Yao Yin, Nan-Ge Liu, Fang Jia, Yun-Tao Liu, Yao |
author_sort | Song, Lin |
collection | PubMed |
description | Population pharmacokinetic (PPK) modelling is an easy and impartment method for estimating drug concentration for use inindividualized therapy, especially for young patients and to help protect drug-induced diseases. The purpose of this study was to develop a PPK model for effective dosing of vancomycin in Chinese neonates and young infants. The PPK modelling tool Phoenix(®) NLME(™) was use to assess demographic and routine clinical pharmacokinetic (PK) data retrospectively collected for patients admitted to Children's Hospital of Chongqing Medical University between 2011 and 2016. Data of patients admitted to the hospital between January and June of 2017 were used in validation study, and the final model was also preliminary validated in 2 cases in another hospital. A total of 421 serum samples from 316 patients were included in the initial PPK analysis. A two-compartment PPK model was developed, and exponential-error model was used to describe inter-individual variability of clearance. Residual variability was described by an additive model. The final PPK model was demonstrated as valid by internal and external model evaluation. Of note, the clearance and volume of vancomycin in Chinese neonates and young infants may be greater than in Caucasians. Herein, we describe the establishment of an accurate PPK model of vancomycin for Chinese neonates and young infants, which may be useful as a dosing algorithm for this particular paediatric population. |
format | Online Article Text |
id | pubmed-5739632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57396322017-12-28 A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants Song, Lin He, Cui-Yao Yin, Nan-Ge Liu, Fang Jia, Yun-Tao Liu, Yao Oncotarget Research Paper Population pharmacokinetic (PPK) modelling is an easy and impartment method for estimating drug concentration for use inindividualized therapy, especially for young patients and to help protect drug-induced diseases. The purpose of this study was to develop a PPK model for effective dosing of vancomycin in Chinese neonates and young infants. The PPK modelling tool Phoenix(®) NLME(™) was use to assess demographic and routine clinical pharmacokinetic (PK) data retrospectively collected for patients admitted to Children's Hospital of Chongqing Medical University between 2011 and 2016. Data of patients admitted to the hospital between January and June of 2017 were used in validation study, and the final model was also preliminary validated in 2 cases in another hospital. A total of 421 serum samples from 316 patients were included in the initial PPK analysis. A two-compartment PPK model was developed, and exponential-error model was used to describe inter-individual variability of clearance. Residual variability was described by an additive model. The final PPK model was demonstrated as valid by internal and external model evaluation. Of note, the clearance and volume of vancomycin in Chinese neonates and young infants may be greater than in Caucasians. Herein, we describe the establishment of an accurate PPK model of vancomycin for Chinese neonates and young infants, which may be useful as a dosing algorithm for this particular paediatric population. Impact Journals LLC 2017-10-26 /pmc/articles/PMC5739632/ /pubmed/29285245 http://dx.doi.org/10.18632/oncotarget.22114 Text en Copyright: © 2017 Song et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Song, Lin He, Cui-Yao Yin, Nan-Ge Liu, Fang Jia, Yun-Tao Liu, Yao A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants |
title | A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants |
title_full | A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants |
title_fullStr | A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants |
title_full_unstemmed | A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants |
title_short | A population pharmacokinetic model for individualised dosage regimens of vancomycin in Chinese neonates and young infants |
title_sort | population pharmacokinetic model for individualised dosage regimens of vancomycin in chinese neonates and young infants |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739632/ https://www.ncbi.nlm.nih.gov/pubmed/29285245 http://dx.doi.org/10.18632/oncotarget.22114 |
work_keys_str_mv | AT songlin apopulationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT hecuiyao apopulationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT yinnange apopulationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT liufang apopulationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT jiayuntao apopulationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT liuyao apopulationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT songlin populationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT hecuiyao populationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT yinnange populationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT liufang populationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT jiayuntao populationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants AT liuyao populationpharmacokineticmodelforindividualiseddosageregimensofvancomycininchineseneonatesandyounginfants |